Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.

[1]  N. Girard,et al.  LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial , 2021, Annals of Oncology.

[2]  N. Girard,et al.  PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. , 2021, Clinical lung cancer.

[3]  B. Bonanni,et al.  Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. , 2021, European journal of cancer.

[4]  A. Chinnaiyan,et al.  Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination , 2021, Nature Medicine.

[5]  Jun Wang,et al.  Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment , 2020, Frontiers in Immunology.

[6]  Tomoaki Yamada,et al.  Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. , 2020, The Lancet. Oncology.

[7]  G. Giaccone,et al.  Thymic epithelial tumors: From biology to treatment. , 2020, Cancer treatment reviews.

[8]  A. Mammen,et al.  Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma , 2019, Journal of Immunotherapy for Cancer.

[9]  E. V. Van Allen,et al.  Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. , 2019, JAMA oncology.

[10]  J. Ahn,et al.  Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Hosomi,et al.  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. , 2019, European journal of cancer.

[12]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[13]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[14]  G. Giaccone,et al.  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. , 2018, The Lancet. Oncology.

[15]  Mark W. Ball,et al.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.

[16]  Benjamin J. Raphael,et al.  The Integrated Genomic Landscape of Thymic Epithelial Tumors. , 2018, Cancer cell.

[17]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[18]  A. Nicholson,et al.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  H. Sasaki,et al.  A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[21]  C. Langer,et al.  Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Y. Monden,et al.  Follow‐up study of thymomas with special reference to their clinical stages , 1981, Cancer.

[23]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[24]  B. Frémont,et al.  SUMMARY OF SAFETY AND EFFECTIVENESS DATA , 2002 .